Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

NCT02649764 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Chronic Myelomonocytic Leukemia
Recurrent Acute Myeloid Leukemia
Recurrent High Risk Myelodysplastic Syndrome
Refractory Acute Myeloid Leukemia
Refractory High Risk Myelodysplastic Syndrome

Interventions

DRUG: Cytarabine
DRUG: Fludarabine Phosphate
OTHER: Laboratory Biomarker Analysis
DRUG: Prexasertib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]